Tinnitus has no cure. No FDA-approved treatment. No pharmaceutical company racing to solve it. ExtraLife Research is building the research program that traditional medicine refuses to fund — combining stem cells, peptides, and psychedelic-assisted therapy to attack this from every angle.
740M+
Adults affected globally
2.3M+
Veterans with VA disability
$2.26B
VA annual spending (FY2022)
0
FDA-approved cures
Three Regenerative Approaches
No single therapy will cure tinnitus. Our hypothesis: combining regenerative approaches that target different mechanisms — cellular repair, nerve regeneration, and neural rewiring — gives us the best chance.
Mesenchymal stem cells target damaged cochlear hair cells and auditory neurons, promoting regeneration at the cellular level.
BPC-157, TB-4, and custom neuroprotective peptide stacks reduce neuroinflammation and support auditory nerve repair.
Psilocybin and MDMA-assisted protocols help rewire maladaptive auditory cortex patterns through neuroplasticity.
The Structural Problem
The science exists. The will exists. But the system — financial incentives, regulatory frameworks, and research silos — was never built to solve a problem like this.
In mammals, damaged inner ear hair cells are permanently lost. Unlike birds and fish that regrow them naturally, humans have no biological repair mechanism. Once they're gone, they're gone — until now.
Tinnitus has no biomarker, no definitive diagnostic test, and no clear drug target. Without a patentable molecule aimed at a measurable outcome, pharmaceutical economics simply look the other way.
Modern neuroscience shows tinnitus is a disorder of neural plasticity — the brain rewires itself to amplify a phantom signal. Treating the ear alone will never be enough.
Combination therapies crossing stem cells, peptides, and psychedelics don't fit neatly into existing FDA pathways. The regulatory structure itself is a barrier to innovation.
The ExtraLife Approach
We're not waiting for Big Pharma. ExtraLife Research is building a physician-backed, patient-driven research engine that puts outcomes above profits.
Research priorities set by the people who live with this condition — patients, veterans, physicians, and advocates. No corporate gatekeepers. No misaligned incentives.
Research intellectual property is tokenized through Molecule.to's IP-NFT framework. Contributors get governance rights over research direction and IP commercialization.
Every dollar tracked. Every study published open-access. Every milestone reported to the community. This is research with radical transparency built in.
Seed Funding
$100K
Community + IP-NFT sale
Pilot Study
$300-500K
N=20-30, 12-week trial
Clinical Trials
$3M+
Phase II multi-site
Research Roadmap
A phased approach to building the evidence base for regenerative tinnitus therapy.
Q2-Q3 2026
Q4 2026 - Q1 2027
Q2-Q4 2027
2028+
Explore the Research
Why 740M people are suffering in silence
ExploreOur three-pillar research approach
ExploreFund the research. Own the IP.
ExploreJoin 1,000+ people ready for trials
ExploreSupport the mission and help move tinnitus research forward
ExploreExploring legal psychedelic-assisted pathways for tinnitus
ExploreHow community-backed research is changing science
Explore